Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Invested Capital (2019 - 2023)

Coherus Oncology's Return on Invested Capital history spans 4 years, with the latest figure at 1.25% for Q4 2023.

  • For Q4 2023, Return on Invested Capital changed N/A year-over-year to 1.25%; the TTM value through Dec 2023 reached 1.25%, changed N/A, while the annual FY2023 figure was 1.24%, N/A changed from the prior year.
  • Return on Invested Capital for Q4 2023 was 1.25% at Coherus Oncology, up from 1.2% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 1.25% in Q4 2023 and bottomed at 0.9% in Q3 2021.
  • The 4-year median for Return on Invested Capital is 0.41% (2020), against an average of 0.31%.
  • The largest annual shift saw Return on Invested Capital surged 69bps in 2020 before it plummeted -180bps in 2021.
  • A 4-year view of Return on Invested Capital shows it stood at 0.07% in 2019, then tumbled by -609bps to 0.34% in 2020, then crashed by -162bps to 0.9% in 2021, then soared by 239bps to 1.25% in 2023.
  • Per Business Quant, the three most recent readings for CHRS's Return on Invested Capital are 1.25% (Q4 2023), 1.2% (Q3 2023), and 0.9% (Q3 2021).